4basebio PLC has announced the supply of its HQ synthetic DNA to a Tier 1 Pharma Company for their mRNA vaccine program. The company has successfully completed an opDNA™ evaluation study, leading to the progression to HQ opDNA™ for late preclinical studies. The supply of GMP grade material for clinical trials is anticipated in Q3. Dr. Heikki Lanckriet, CEO at the Company, expressed that this achievement is significant in terms of product quantity and value, highlighting the strengths of their synthetic DNA products, product quality, and manufacturing capabilities.

Dr. Lanckriet also mentioned the strong interest in their synthetic DNA products and the increasing support for clinical projects. The company expects client acquisition and revenue generation to continue accelerating as their expanding client base progresses their clinical programs. 4basebio is an innovation-driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The company aims to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic, and pharmacological use, as well as the development of target-specific non-viral vectors for efficient payload delivery in patients.

The company is offering GMP compliant DNA starting materials suitable for use in AAV viral vector production, as well as mRNA vaccine and therapeutics production. The announcement may contain forward-looking statements about the future outlook for 4basebio, with the directors acknowledging that any statements about the future outlook may be influenced by factors that could cause actual outcomes and results to be materially different.